Simulations Plus, Inc. develops drug discovery and development software for mechanistic modeling, simulation, and prediction of molecule properties using artificial intelligence and machine learning technology worldwide. The company is headquartered in Lancaster, California.
| Revenue (TTM) | $82.06M |
| Gross Profit (TTM) | $52.01M |
| EBITDA | $15.02M |
| Operating Margin | 22.80% |
| Return on Equity | 6.17% |
| Return on Assets | 5.48% |
| Revenue/Share (TTM) | $4.07 |
| Book Value | $6.88 |
| Price-to-Book | 2.68 |
| Price-to-Sales (TTM) | 4.54 |
| EV/Revenue | 3.937 |
| EV/EBITDA | 18.87 |
| Quarterly Earnings Growth (YoY) | 46.70% |
| Quarterly Revenue Growth (YoY) | 7.50% |
| Shares Outstanding | $20.22M |
| Float | $16.81M |
| % Insiders | 16.91% |
| % Institutions | 79.44% |
Volatility is currently contracting
SAN DIEGO, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating Simulations Plus, Inc. (NASDAQ: SLP) for investors who suffered losses and whether they may recover those losses under federal securities laws.
SAN DIEGO, Aug. 20, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating Simulations Plus, Inc. (NASDAQ: SLP) for investors who suffered losses and whether they may recover those losses under federal securities laws. On April 3, 2025, Simulations Plus reported its financial results for the second quarter of fiscal 2025 and maintained full-year revenue guidance of $90 million to $93 million.
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus” or the “Company”), a global leader in model-informed and AI-accelerated drug development that advances biopharma innovation, announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 in connection with the Company's previously announced acquisition by Altaris, LLC. The expiration of the HSR waiting period satisfies one of the regulatory cond.
SAN DIEGO, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating Simulations Plus, Inc. (NASDAQ: SLP) on behalf of investors who suffered losses and whether those losses may be recoverable under federal securities laws.
San Diego, California--(Newsfile Corp. - July 29, 2026) - Robbins LLP announces that it is investigating Simulation Plus, Inc. (NASDAQ: SLP) to determine whether certain officers and directors violated securities laws or breached fiduciary duties owed to shareholders The investigation concerns whether Simulation Plus made materially false or misleading statements or omitted material information regarding its financial reporting, internal controls, and business outlook. Investors who purchased Simulation Plus securities and suffered losses may have legal rights.
SAN DIEGO, July 28, 2026 /PRNewswire/ -- Robbins LLP announces that it is investigating Simulation Plus, Inc. (NASDAQ: SLP) to determine whether certain officers and directors violated securities laws or breached fiduciary duties owed to shareholders. The investigation concerns whether Simulation Plus made materially false or misleading statements or omitted material information regarding its financial reporting, internal controls, and business outlook.
SAN DIEGO--(BUSINESS WIRE)---- $SLP #SimulationPlus--Robbins LLP announces that it is investigating Simulation Plus, Inc. (NASDAQ: SLP) to determine whether certain officers and directors violated securities laws or breached fiduciary duties owed to shareholdersThe investigation concerns whether Simulation Plus made materially false or misleading statements or omitted material information regarding its financial reporting, internal controls, and business outlook.Investors who purchased Simulation Plus securities and suf.
SAN DIEGO, July 13, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating Simulations Plus, Inc. (NASDAQ: SLP) on behalf of investors who suffered losses and whether those losses may be recoverable under federal securities laws.
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus” or the “Company”), a global leader in model-informed and AI-accelerated drug development that advances biopharma innovation, today reported financial results for its third quarter fiscal 2026, ended May 31, 2026. Third Quarter 2026 Financial Highlights (as compared to third quarter 2025) Total revenue increased 7% to $21.9 million Software revenue was flat at $12.6 million, representing 58% o.
SAN DIEGO, July 08, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating Simulations Plus, Inc. (NASDAQ: SLP) on behalf of investors who suffered losses and whether those losses may be recoverable under federal securities laws.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on SLP and any ticker you trade — then tracks every position and per-strategy win rate.
